Intel IPO delivers better gaming performance than 200S Boost in user benchmarks
Intel has recently introduced two performance-boosting features for its Core Ultra 200S (codenamed Arrow Lake) processors, which rank among the best CPUs. While IPO (Intel Performance Optimizations) and 200S Boost share the same objective, one BiliBili user's tests (via Uniko's Hardware) seemingly show that IPO delivers a higher gaming performance uplift.
The user performed the tests with a Core Ultra 7 265K, DDR5-8000 memory, and a GeForce RTX 5090D. They benchmarked IPO and 200S Boost across seven games with different quality settings at 2160p (3840 x 2160) and DLSS activated when applicable.
The Core Ultra 7 265K was a part of three configurations. The XMP configuration enables XMP to get the memory up to DDR5-8000 with no changes to the processor. The 200S Boost configuration increases the Die-to-Die (D2D) communication fabric from the default 2.1 GHz to 3.2 GHz and the Next Generation Uncore (NGU) fabric from 2.6 GHz to 3.2 GHz.
On the other hand, the IPO configuration makes several changes to the processor. For starters, it increases the P-core and E-core clocks to 5.4 GHz and 4.9 GHz, respectively, from the default 5.2 GHz and 4.9 GHz. While the 200S Boost doesn't touch the Ring (3.8 GHz), IPO overclocks it to 4 GHz. These adjustments limit IPO from pushing the D2D and NGU as hard as 200S Boost. As a result, the IPO only dials in at 3.1 GHz for the D2D and NGU. The memory, however, is tuned to DDR5-8400 with optimized timings.
IPO pumped out 2% higher average frame rates than 200S Boost in Forza Horizon 5 and less than 1% higher 1% Lows. In Cyberpunk 2077, however, IPO exhibited 3% higher average frame rates and 6% higher 1% Lows. IPO also excelled in Total War: Warhammer III, delivering 6% better average frame rates and 9% better 1% Lows than 200S Boost.
With Black Myth: Wukong, IPO only showed 2% higher average frame rates and 1% Lows than 200S Boost. The tests showed similar results in Tom Clancy's Rainbow Six: Siege.
Counter-Strike 2, tested at 1080p (1920 x 1080), gained the most from Intel's performance enhancements. It is not unexpected, as Counter-Strike 2 is very processor-intensive. IPO boasted 16% higher average frame rates and 20% better 1% Lows. Meanwhile, IPO outperformed 200S Boost in Watch Dogs: Legion with 8% and 9% improved average frame rates and 1% Lows, respectively.
Since their introduction, Intel's Core Ultra 200S processors have exhibited performance challenges, prompting Intel to develop various optimizations to enhance their competitiveness against AMD's Ryzen 9000 (codename Granite Ridge) processors. Nonetheless, user-provided benchmarks indicate a comparative advantage for Intel IPO over 200S Boost. It's understandable since the former makes more changes to the processor's parameters and overclocks compatible DDR5-8000 memory kits to DDR5-8400.
As the results have shown, the performance margins between Intel's IPO and 200S Boost are small unless you're playing a processor-intensive game. For instance, running Cyberpunk 2077 at 289 FPS or 297 FPS may not be discernible to the human eye if you don't have a frame rate monitoring software on screen.
Intel's 200S Boost is available to all Arrow Lake processor owners via a motherboard firmware update. Intel IPO, on the other hand, is currently only available in China.
Follow Tom's Hardware on Google News to get our up-to-date news, analysis, and reviews in your feeds. Make sure to click the Follow button.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Why Voyager Technologies Stock Crashed Today
Key Points Voyager Technologies missed badly on earnings last night. Losses were more than twice what Wall Street had expected. Voyager's defense business is doing its best to offset losses from the space program, but there are a lot of losses to offset. 10 stocks we like better than Voyager Technologies › It's been a little over a month since I first warned investors about the danger of investing in a new space stock, space station builder Voyager Technologies (NYSE: VOYG). After a smashingly successful IPO, Voyager's stock price flipped head over tail and began falling. And why? Simply put, Voyager has years of costs ahead of it before it gets a space station in orbit, and whether it ever becomes profitable after that "is anyone's guess," as I warned in June. One thing's certain, though: Voyager definitely wasn't profitable in Q2. And now its stock is down another 17.3% (through 1:15 p.m. ET today). Voyager Technologies Q2 earnings Reporting Q2 results last night, Voyager fessed up to a $0.60-per-share loss -- twice what Wall Street feared -- despite generating sales of $45.7 million, ahead of the forecast. Sales came (perhaps obviously) not from the space stations that Voyager hasn't built yet but rather from the company's defense business, which builds missiles for the military, and where sales grew 85%. Losses were in part due to "non-recurring costs associated with the Company's IPO," which is at least somewhat reassuring. Is Voyager stock a sell? Less reassuring is company guidance. Management noted that full-year sales will range from $165 million to $170 million in 2025, which is ahead of analyst forecasts. However, on earnings, management noted only that "adjusted EBITDA" will show a loss, and it said not a word about its likely losses as calculated according to generally accepted accounting principles (GAAP), or about free cash flow, either. Voyager did note that it is "debt-free" and has "total liquidity of $669 million," suggesting the company should be able to burn cash for some time before it runs out. The bad news: It will probably have to. Should you invest $1,000 in Voyager Technologies right now? Before you buy stock in Voyager Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Voyager Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Voyager Technologies Stock Crashed Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Heartflow stock listing and IPO date draw near: AI-powered medtech aims for $1.3 billion valuation
It seems there's fresh blood pumping back into the IPO market. After a blowout initial public offering from Figma last week, investors might have another chance to get their heart rates up again soon. AT&T to pay $177 million in data breach settlement. Here's how to claim up to $5,000 Wells Fargo is rolling out company wide AI. It says everyone from branch tellers to investment bankers will benefit Want to get smarter? Neuroscience says 5 simple steps significantly boost memory, learning, and cognition Heartflow, a California-based medtech company that utilizes AI with imaging and diagnostics software to help evaluate cardiac and coronary diseases, is looking to list shares on the Nasdaq. In paperwork filed on Friday with the Securities and Exchange Commission (SEC), Heartflow said it plans to offer 12.5 million shares, priced between $15 and $17. That could potentially raise more than $208 million. According to Reuters, Heartflow's target valuation could be as high as $1.3 billion. The company plans to trade under the ticker 'HTFL.' Personalized 3D-models of people's hearts Heartflow uses AI and other technology to scan patients for coronary and cardiac problems, creating three-dimensional models of patients' hearts. The Food and Drug Administration (FDA) gave the software the green light in 2022, and it's now being used in some markets to diagnose patients. Additionally, the company got a leg up last year when the U.S. Centers for Medicare and Medicaid Services (CMS) expanded Medicare coverage to include platforms that use imaging results to look for signs of coronary disease, and the American Medical Association (AMA) issued a new Category I CPT code for those platforms. That gives doctors and clinics the go-ahead to start using the technology on a broader scale starting next year. According to the company's SEC filing, Heartflow says that as of the end of March 2025, it's been used to assess more than 400,000 patients. Revenues are growing but profits are elusive Heartflow generated $125.8 million in 2024, a 44% increase over the $87.2 million it made the year before, the company says. Revenue likewise grew 39% for the first quarter of 2025 to $37.2 million. However, the company saw a net loss of $96.4 million in 2024, wider than its net loss of $95.7 million in 2023. It warns in the filing that it expects to incur 'substantial losses in the foreseeable future [and] may not be able to achieve or sustain profitability.' Bain Capital, Panorama Point Partners, and Capricorn Investment Group are among Heartflow's backers, according to Crunchbase. Bain led its most recent fundraising round, a Series F round in 2023, which raised $215 million. This is not the first time that Heartflow has attempted to go public. The company had planned to merge with a special purpose acquisition company during the SPAC frenzy of the early pandemic years, but it halted the plan in 2022, citing 'unfavorable market conditions,' as Fierce Biotech reported. Heartflow's IPO comes on the heels of another growing medtech company's public debut. Carlsmed, which specializes in AI-driven spine surgery technology, recently went public as well, with shares trading on July 23. Since then, the stock is down around 4.5%. Heartflow has not said when it plans to list its stock, although IPO calendar websites say the listing is expected this week. The company declined to comment on the timeline when reached by Fast Company. This post originally appeared at to get the Fast Company newsletter: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
4 hours ago
- Epoch Times
Sen. Cotton Questions Intel on New CEO's China Ties
Sen. Tom Cotton (R-Ark.) has written to Intel seeking information about the company's new CEO, raising questions about CEO Tan Lip-Bu's investments in Chinese firms with links to the People's Liberation Army, the military wing of the Chinese Communist Party. The tech giant has recently received billions in federal funding, including from a U.S. national security program.
